Johannes A Bogaards

Summary

Affiliation: Crucell Holland BV
Country: The Netherlands

Publications

  1. ncbi Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings: efficiency related to active case finding
    Johannes A Bogaards
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 41:232-7. 2006
  2. ncbi Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis
    Johannes A Bogaards
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands
    Antivir Ther 8:43-50. 2003
  3. ncbi Meeting the immense need for HAART in resource-poor settings
    Johannes A Bogaards
    Departments of Human Retrovirology, Clinical Epidemiology and Biostatistics, University of Amsterdam, Amsterdam, The Netherlands
    J Antimicrob Chemother 52:743-6. 2003
  4. ncbi Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia
    Jaap Goudsmit
    Department of Human Retrovirology, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    AIDS 16:791-3. 2002
  5. ncbi Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants
    Jan Ter Meulen
    Crucell Holland B V, Leiden, Netherlands
    PLoS Med 3:e237. 2006
  6. ncbi AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination
    Marijn van Ballegooijen
    Institute for Biodiversity and Ecosystem Dynamics, Faculty of Science, University of Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 34:214-20. 2003
  7. ncbi Is population-level perversity a likely outcome of mass vaccination against HIV?
    Johannes A Bogaards
    Lancet Infect Dis 5:254; author reply 255-6. 2005

Collaborators

Detail Information

Publications7

  1. ncbi Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings: efficiency related to active case finding
    Johannes A Bogaards
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 41:232-7. 2006
    ..Plasma viral load testing can ensure a more efficient allocation of antiretroviral therapy but only when applied to a strategy of active case finding in the community...
  2. ncbi Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis
    Johannes A Bogaards
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands
    Antivir Ther 8:43-50. 2003
    ..In a hospital-based setting in resource-poor environments this ensures an efficient treatment allocation...
  3. ncbi Meeting the immense need for HAART in resource-poor settings
    Johannes A Bogaards
    Departments of Human Retrovirology, Clinical Epidemiology and Biostatistics, University of Amsterdam, Amsterdam, The Netherlands
    J Antimicrob Chemother 52:743-6. 2003
  4. ncbi Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia
    Jaap Goudsmit
    Department of Human Retrovirology, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    AIDS 16:791-3. 2002
  5. ncbi Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants
    Jan Ter Meulen
    Crucell Holland B V, Leiden, Netherlands
    PLoS Med 3:e237. 2006
    ..Combinations of virus-neutralizing, noncompeting mAbs may have these properties...
  6. ncbi AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination
    Marijn van Ballegooijen
    Institute for Biodiversity and Ecosystem Dynamics, Faculty of Science, University of Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 34:214-20. 2003
    ..The number of long-term survivors is substantially increased only when vaccination is initiated early in an AIDS epidemic, however...
  7. ncbi Is population-level perversity a likely outcome of mass vaccination against HIV?
    Johannes A Bogaards
    Lancet Infect Dis 5:254; author reply 255-6. 2005